A carregar...

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

AZD3409 is an orally active double prodrug that was developed as a novel dual prenyltransferase inhibitor. The formation of the active metabolite AZD3409 acid is mediated by esterases in plasma and cells. The aim of this phase I study was to determine the maximum tolerated dose, toxicities, pharmaco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Appels, N M G M, Bolijn, M J, Chan, K, Stephens, T C, Hoctin-Boes, G, Middleton, M, Beijnen, J H, de Bono, J S, Harris, A L, Schellens, J H M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2008
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2441954/
https://ncbi.nlm.nih.gov/pubmed/18506143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!